349 related articles for article (PubMed ID: 35148401)
1. The Challenges of Predicting Drug-Induced QTc Prolongation in Humans.
Valentin JP; Hoffmann P; Ortemann-Renon C; Koerner J; Pierson J; Gintant G; Willard J; Garnett C; Skinner M; Vargas HM; Wisialowski T; Pugsley MK
Toxicol Sci; 2022 Apr; 187(1):3-24. PubMed ID: 35148401
[TBL] [Abstract][Full Text] [Related]
2. Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium.
Park E; Gintant GA; Bi D; Kozeli D; Pettit SD; Pierson JB; Skinner M; Willard J; Wisialowski T; Koerner J; Valentin JP
Br J Pharmacol; 2018 Feb; 175(4):606-617. PubMed ID: 29181850
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
4. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
[TBL] [Abstract][Full Text] [Related]
5. ICH S7B In Vitro Assays Do Not Address Mechanisms of QT
Wu WW; Choe M; Johannesen L; Vicente J; Bende G; Stockbridge NL; Strauss DG; Garnett C
Clin Pharmacol Ther; 2023 Dec; 114(6):1332-1341. PubMed ID: 37702218
[TBL] [Abstract][Full Text] [Related]
6. Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine.
Patel N; Wisniowska B; Polak S
AAPS J; 2018 Jul; 20(5):83. PubMed ID: 29995258
[TBL] [Abstract][Full Text] [Related]
7. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
[TBL] [Abstract][Full Text] [Related]
8. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
9. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
10. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).
Strauss DG; Wu WW; Li Z; Koerner J; Garnett C
Clin Pharmacol Ther; 2021 Feb; 109(2):319-333. PubMed ID: 33332579
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
Gintant G
Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
[TBL] [Abstract][Full Text] [Related]
12. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
13. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
[TBL] [Abstract][Full Text] [Related]
14. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
15. Molecular predictors of drug-induced prolongation of the QT interval.
Dilaveris PE
Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
[TBL] [Abstract][Full Text] [Related]
16. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
17. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
Finlayson K; Witchel HJ; McCulloch J; Sharkey J
Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
[TBL] [Abstract][Full Text] [Related]
18. Predicting drug-induced QT prolongation and torsades de pointes: a review of preclinical endpoint measures.
Townsend C; Brown BS
Curr Protoc Pharmacol; 2013 Jun; Chapter 10():Unit 10.16. PubMed ID: 23744708
[TBL] [Abstract][Full Text] [Related]
19. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
[TBL] [Abstract][Full Text] [Related]
20. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays.
Wallis RM
Br J Pharmacol; 2010 Jan; 159(1):115-21. PubMed ID: 19785646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
